The firm's personalized immunotherapy DISP-10 combines an engineered tumor-specific virus with BMS's CAR T-cell therapy Abecma.
NEW YORK – OneOncology, a network of community oncology practices, on Thursday said it will embed OpenEvidence's artificial intelligence-based chatbot and search engine in its clinics to help ...
NEW YORK – Rocket Pharmaceuticals is discussing next steps to complete a pivotal Phase II trial of its Danon disease gene therapy, RP-A501, with the US Food and Drug Administration based on promising ...
The firm's approved product Avmapki Fakzynja Co-Pack also returned to sequential growth in Q2 helped by a refocused commercial strategy.
If the FDA approves lonvo-z, Intellia expects it will be able to launch the drug, its first commercial product, in the first ...
The firm, founded based on research from Zhejiang University, is partnering with Walvax for logistical support for the investigator-initiated trial.
The firm also expects topline data from a trial of its gene therapy for rare eye diseases caused by mutations in the BEST1 gene in September.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results